semaglutide step 2 Day 2: Wegovy (Semaglutide 2.4 mg weekly injection) Class: GLP-1 receptor agonist Avg Weight Loss: ~15% of baseline weight Dosing: Weekly subcutaneous injection FDA Approved: June 2021 for chronic weight management Pros Efficacy and safety of once

Cardiovascular and Endothelial Benefits GLP-1 RAs have demonstrated robust cardiovascular protection in multiple large-scale trials, including LEADER, REWIND, and SUSTAIN-6, showing reduced rates of major adverse cardiac events independent of weight loss

Because GLP-1 significantly reduce appetite, many women unintentionally consume fewer calories, especially when preparing their bodies for pregnancy

MET activation is involved in angiogenesis, wound healing, cell scattering, proliferation, and cancer invasion (Trusolino et al., 2010)

These include: Call us today if youre ready to experience a healthier, happier you

Take it as soon as you remember, unless it is almost time for your next dose